CD137 (4-1BB) is a positive regulator of the immune system that is highly upregulated on activated T cells (adaptive immune cells) and NK cells (innate immune cells). The potential to dually target innate and adaptive immunity makes CD137 a highly attractive target for cancer immunotherapy. AGEN2373 is a fully human monoclonal antibody that boosts the immune response to cancer cells by enhancing CD137 co-stimulatory signaling in activated immune cells. Importantly, the unique binding properties of AGEN2373 are expected to limit its activity outside of the tumor site and mitigate toxicities that may be associated with systemic activation of CD137 in humans.

AGEN2373 is advancing in a clinical trial against solid tumors.

Latest Clinical Trials

Solid tumors


Phase 1, open-label, 3+3 dose escalation design Phase I trial to assess the safety, tolerability and dose-limiting toxicity (DLT) of AGEN2373 as monotherapy in subjects with solid tumors

Latest Publications and Abstracts

American Society of Clinical Oncology (ASCO)

June 3-7, 2021

Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors. Tolcher, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects. Galand, et al.

Society for Immunotherapy of Cancer (SITC)

November 7-11, 2018

AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies. Galand, et al.